NSCLC
Conditions
Keywords
Genomic Aberrations, Exactis Network, Advanced or Metastatic Non-Small Cell Lung Cancer, Liquid Biopsy
Brief summary
A Multi-centre Observational Study to Evaluate the Clinical Utility of Returning Genomic Aberration results Using the Oncomine Precision Assay in Advanced or Metastatic Non-Small Cell Lung Cancer Patients within the Exactis Network
Detailed description
This prospective multi-center observational study will evaluate the clinical utility of returning genomic aberration results in blood and/or tissue using the Oncomine Precision Assay in non-small cell lung cancer (NSCLC) patients. Up to 100 patients with stage IIIb/IV NSCLC will consent to have their blood and tissue profiled on the Oncomine Precision Assay. A baseline plasma sample will be collected for all patients, of which up to 50 patients will have a tissue sample collected from pathology archives or planned biopsy or surgery.
Interventions
None listed
Sponsors
Exactis Innovation
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients with NSCLC, which is (i) advanced or metastatic (stage IIIb/IV), (ii) non- squamous histology NSCLC as confirmed by local histopathology (mixed squamous and adenocarcinoma is allowed), and has (iii) radiographically measurable disease with at least one bidimensionally measurable lesion of \> 1 cm by CT scan * No prior treatment for advanced or metastatic NSCLC, except for palliative radiation therapy to non-lung or non-thorax metastases. Patients who received palliative radiation therapy to metastases located within or approximately to the lung or thorax must be evaluated for eligibility. * Willing and able to provide adequate blood sample prior to starting treatment. * Willing to provide primary or metastatic tissue, if available. * Signed and dated Research Ethics Board (REB)-approved informed consent form for Exactis-01 or PMT. * Not pregnant or breastfeeding
Exclusion criteria
• Patients who have a history of another active cancer within the past 2 years from date of consent except cervical cancer in situ, basal cell carcinoma of the skin or another in situ carcinoma that is considered cured by the investigator.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| To compare the number of genomic aberrations detected by the Oncomine Precision Assay vs Standard of Care | 1 year | Proportion of patients for whom an actionable genomic aberration is detected in at least one of the eight genes (ROS1, ERBB2, MET, BRAF, KRAS, RET, ALK, EGFR) using the Oncomine Precision Assay vs. study site's standard of care |
Secondary
| Measure | Time frame |
|---|---|
| Clinical utility of returning genomic aberration results by quantifying the number of patients who received targeted therapy based on results returned from the Oncomine Precision Assay genomic aberration results in blood and/or tissue | 2 years |
| Clinical utility of returning genomic aberration results by quantifying the number of patients enrolled on a clinical trial based on results returned from the Oncomine Precision Assay in blood and/or tissue | 2 years |
Other
| Measure | Time frame | Description |
|---|---|---|
| Exploratory - Analytical validity of Oncomine Precision Assay | 2 years | Number of genomic aberrations concordant and discordant between tissue and blood using the Oncomine Precision Assay |
| Exploratory- Sensitivity and specificity of mutation detection analysis of extracellular vesicles (EV) total nucleic acids | 2 years | Compare the sensitivity and specificity of mutation detection in extracellular vesicles (EV) total nucleic acids and circulating tumor total nucleic acids |
| Exploratory- Explore the response patterns to treatment based on EV RNAs | 2 years | Small RNA extracted from plasma EV at baseline and at progression will be analyzed using RNA sequencing. Potential association between expression profiles and clinical parameters such as treatment response will be explored and candidate patterns predictive of treatment response will be tested using artificial intelligence algorithms. |
Countries
Canada
Outcome results
None listed